Medpace Q3 revenue rises 8.5%, slightly beats analyst estimates

Medpace Holdings

Yesterday 21:23

Overview
US clinical research firm's Q3 revenue rose 8.5%, slightly beating analyst expectations
Q3 net income grew to $137.5 mln, with net income margin rising to 19.2%
Company approved new $1 bln share repurchase authorization, replacing prior program

Outlook
Medpace forecasts 2026 revenue of $2.835 bln to $2.855 bln
Company expects 2026 GAAP net income of $514 mln to $524 mln
Medpace projects 2026 diluted EPS of $17.97 to $18.32

Result Drivers
NEW BUSINESS AWARDS - Net new business awards rose 10.6% year-on-year to $873.4 mln, supporting revenue growth

Company press release: ID:nBw7ptB2Va

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$716 mln
$715.98 mln (12 Analysts)
Q3 Net Income
 
$137.46 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Medpace Holdings, Inc. is $615.00, about 1.2% below its October 20 closing price of $622.43
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 30 three months ago

Reuters Recommended Reads
Oct 20 - RTX beats Q3 earnings expectations, lifts guidance amid robust demand
Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches
Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)